A Philadelphia jury has handed up a defense verdict in the latest trial over the adequacy of the warning labels for the blood thinner Xarelto.

The verdict marked the second straight defense verdict out of Philadelphia for drugmakers Bayer and Janssen Pharmaceuticals, which saw similar wins in a string of cases tried last year in federal court. The decision Thursday was rendered after three weeks of trial, and less than a day of jury deliberation.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]